Clinical significance of serum interleukin-6 and -174 G/C promoter polymorphism in Rheumatoid arthritis patients

Egyptian Rheumatologist

Volumn 35, Issue 2, 2013, Pages 107-113

  Gaber, Wafaa ^a   Azkalany, Ghada S ^a   Gheita, Tamer A ^a   Mohey, Abeer ^a   Sabry, Randa ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

( 174 G C) Promoter polymorphism; IL 6; Rheumatoid arthritis

Indexed keywords

CHLOROQUINE; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; DAS28; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DNA POLYMORPHISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL DISEASE; GENOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SEROLOGY; THROMBOCYTE COUNT;

EID: 84880395829     PISSN: 11101164     EISSN: 20902433     Source Type: Journal    
DOI: 10.1016/j.ejr.2012.11.002     Document Type: Article

References (37)

1. Perricone C., Ceccarelli F., Valesini G. An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun Rev 2011, 10(10):599-608.
2. Nile C.J., Read R.C., Akil M., Duff G.W., Wilson A.G. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 2008, 58(9):2686-2693.
3. Marinou I., Healy J., Mewar D., Moore D.J., Dickson M.C., Binks M.H., et al. Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status. Arthritis Rheum 2007, 56:2549-2556.
4. Pawlik A., Wrzesniewska J., Florczak M., Gawronska-Szklarz B., Herczynska M. IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 2005, 34(2):109-113.
5. Fonseca J.E., Santos M.J., Canhão H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8(7):538-542.
6. Chung S.J., Kwon Y.J., Park M.C., Park Y.B., Lee S.K. The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 2011, 52(1):113-120.
7. Fabris M., Quartuccio L., Lombardi S., Benucci M., Manfredi M., Saracco M., et al. Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis. Reumatismo 2010, 62(4):253-258.
8. Pascual M., Nieto A., Matarán L., Balsa A., Pascual-Salcedo D., Martín J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000, 1(5):338-340.
9. Marinou I., Walters K., Winfield J., Bax D.E., Wilson A.G. A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility. Ann Rheum Dis 2010, 69(6):1191-1194.
10. Jones K.G., Brull D.J., Brown L.C., Sian M., Greenhalgh R.M., Humphries S.E., et al. Interleukin-6, (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001, 103:2260-2265.
11. Humphries S.E., Luong L.A., Ogg M.S., Hawe E., Miller G.J. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001, 22(24):2243-2252.
12. Mosaad Y.M., Fathy H., Fawzy Z., El-Saied M.A. Tumor necrosis factor-α -308 G>A and interleukin-6 -174 G>C promoter polymorphisms and pemphigus. Hum Immunol 2012, 73(5):560-565.
13. Palomino-Morales R., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., Llorca J., Martin J., et al. Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol 2009, 27(6):964-970.
14. Murakami M., Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol 2011, 23(3):273-277.
15. Assier E., Boissier M.C., Dayer J.M. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010, 77(6):532-536.
16. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761-1769.
17. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581.
18. Prevoo M.L.L., Hof van't M.A., Kuper H.H., Leeuwen van M.A., Putte van de L.B.A., Riel van P.L.C.M. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
19. Wolfe F., Michaud K., Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004, 50:3296-3305.
20. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long term studies. J Rheumatol 1995, 22:1974-1975.
21. Pola R., Flex A., Gaetani E., Pola P., Bemabei R. The -174 G/C polymorphism of the interleukin-6 gene promoter and essential hypertension in an elderly Italian population. J Hum Hypertens 2002, 16(9):637-640.
22. Huang X.Z., Zhuang J.H., Ren Y.G., Zhou L.J., Zhou Q. Association of interleukin-6 and interleukin-18 gene polymorphism with rheumatoid arthritis in Guangdong Han population. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27(11):1661-1664.
23. Brandão F.M., Coelho P., Pinto P., Combe B. Tocilizumab - a new step in rheumatoid arthritis treatment. Acta Reumatol Port 2010, 35(3):302-312.
24. Lee Y.H., Bae S.C., Choi S.J., Ji J.D., Song G.G. The association between interleukin-6 polymorphisms and rheumatoid arthritis: a meta-analysis. Inflamm Res 2012, 61(7):665-671.
25. Fabris M., Quartuccio L., Lombardi S., Saracco M., Atzeni F., Carletto A., et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 2012, 11(5):315-320.
26. Afzal N., Abbas S., Ahmed A., Arif M., Javeed K. Effect of hepatitis C virus on C-reactive protein and interleukin-6 in hemodialysis patients. Iran J Kidney Dis 2011, 5(3):182-186.
27. Guzmán-Fulgencio M., Jiménez J.L., Berenguer J., Fernández-Rodríguez A., López J.C., Cosín J., et al. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients. J Antimicrob Chemother 2012, 67(5):1238-1245.
28. Riccio A., Postiglione L., Sabatini P., Linvelli M., Soriente I., Sangiolo M.G., et al. Similar serum levels of IL-6 and its soluble receptors in patients with HCV-related arthritis and rheumatoid arthritis: a pilot study. Int J Immunopathol Pharmacol 2012, 25(1):281-285.
29. Cussigh A., Falleti E., Fabris C., Bitetto D., Cmet S., Fontanini E., et al. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Immunogenetics 2011, 63(1):33-41.
30. Van Leeuwen M.A., Westra J., Limburg P.C., van Riel P.L., van Rijswijk M.H. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis 1995, 54:674-677.
31. Leffers H.C., Ostergaard M., Glintborg B., Krogh N.S., Foged H., Tarp U., et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice. results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011, 70(7):1216-1222.
32. Ceresa I.F., Noris P., Ambaglio C., Pecci A., Balduini C.L. Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets 2007, 18(8):579-582.
33. Buttgereit F. How should impaired morning function in rheumatoid arthritis be treated?. Scand J Rheumatol Suppl 2011, 125:28-39.
34. Sierakowski S., Cutolo M. Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol Suppl 2011, 125:1-5.
35. Burmester G.R., Feist E., Kellner H., Braun J., Iking-Konert C., Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011, 70(5):755-759.
36. Ceccarelli F., Perricone C., Fabris M., Alessandri C., Iagnocco A., Fabro C., et al. Transforming growth factor-beta 869C/T and interleukin-6 -174G/C polymorphisms relate to the severity and progression of bone erosive damage detected by ultrasound in rheumatoid arthritis. Arthritis Res Ther 2011, 13(4):R111.
37. Pawlik A., Czerny B., Dabrowska-Zamojcin E., Górnik W., Poziomkowska I., Gawrońska-Szklarz B., et al. The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone. Pol Arch Med Wewn 2005, 114(3):843-847.